BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

KPNA3 promotes epithelial–mesenchymal transition by regulating TGF-モ and AKT signaling pathways in MDA-MB-231, a triple-negative breast cancer cell line
Jaesung Choi1,# (Graduate student), Jee-Hye Choi 1,# (Research professor), Ho Woon Lee1,# (Graduate student), Dongbeom Seo1,# (Graduate student), Gavaachimed Lkhagvasuren2 (Graduate student), Jung-Woong Kim1 (Professor), Sang-Beom Seo1 (Professor), Kangseok Lee1 (Professor), Kwang-Ho Lee 1,2,* (Professor)
1Department of Life Science, College of Natural Sciences, and 2Department of Science of Cultural Heritage, Graduate School, Chung-Ang University
Karyopherin-メ3 (KPNA3), a karyopherin- メ isoform, is intimately associated with metastatic progression via epithelial-mesenchymal transition (EMT). However, the molecular mechanism underlying how KPNA3 acts as an EMT inducer remains to be elucidated. In this report, we identified that KPNA3 was significantly upregulated in cancer cells, particularly in triple-negative breast cancer, and its knockdown resulted in the suppression of cell proliferation and metastasis. The comprehensive transcriptome analysis from KPNA3 knockdown cells indicated that KPNA3 is involved in the regulation of numerous EMT-related genes, including the downregulation of GATA3 and E-cadherin and the up-regulation of HAS2. Moreover, it was found that KPNA3 EMT-mediated metastasis can be achieved by TGF-モ or AKT signaling pathways; this suggests that the novel independent signaling pathways KPNA3-TGF-モ-GATA3-HAS2/E-cadherin and KPNA3-AKT-HAS2/E-cadherin are involved in the EMT-mediated progress of TNBC MDA-MB-231 cells. These findings provide new insights into the divergent EMT inducibility of KPNA3 according to cell and cancer type.
Abstract, Accepted Manuscript(in press) [Submitted on November 8, 2022, Accepted on December 29, 2022]
  © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd